Literature DB >> 23389825

[Molecular pathology of the lungs. New perspectives by next generation sequencing].

C Vollbrecht1, K König, L Heukamp, R Büttner, M Odenthal.   

Abstract

Lung cancer is one of the most frequent malignancies in the western world. Its frequent association with a wide spectrum of mutations in genes encoding various signal transducers that are often linked to therapy response, emphasizes the obvious need for improved, fast and highly efficient approaches in molecular pathology. Comprehensive analyses of the mutation status of progression and therapy relevant genes can be performed by the novel sequencing forms named next generation sequencing (NGS) providing extremely high capacities for ultra-deep sequence analyses. The 454 pyrosequencing method, the sequencing by synthesis and the semiconductor sequencing platform are now available for parallel sequencing approaches of multitudinous target genes linked to multiple tumor DNA applications. The "one molecule, one clone, one read" principle by the NGS approaches supplies not only information on allele frequencies and mutation rates but also has the advantage of a very sensitive detection of low frequency variants.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23389825     DOI: 10.1007/s00292-012-1704-7

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  35 in total

1.  Performance comparison of benchtop high-throughput sequencing platforms.

Authors:  Nicholas J Loman; Raju V Misra; Timothy J Dallman; Chrystala Constantinidou; Saheer E Gharbia; John Wain; Mark J Pallen
Journal:  Nat Biotechnol       Date:  2012-05       Impact factor: 54.908

Review 2.  A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer.

Authors:  Peter M Ellis; Normand Blais; Dennis Soulieres; Diana N Ionescu; Meenakshi Kashyap; Geoff Liu; Barb Melosky; Tony Reiman; Phillippe Romeo; Frances A Shepherd; Ming-Sound Tsao; Natasha B Leighl
Journal:  J Thorac Oncol       Date:  2011-08       Impact factor: 15.609

3.  Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.

Authors:  Lecia V Sequist; Joachim von Pawel; Edward G Garmey; Wallace L Akerley; Wolfram Brugger; Dora Ferrari; Yinpu Chen; Daniel B Costa; David E Gerber; Sergey Orlov; Rodryg Ramlau; Susan Arthur; Igor Gorbachevsky; Brian Schwartz; Joan H Schiller
Journal:  J Clin Oncol       Date:  2011-07-18       Impact factor: 44.544

Review 4.  Comprehensive next-generation cancer genome sequencing in the era of targeted therapy and personalized oncology.

Authors:  Maureen Cronin; Jeffrey S Ross
Journal:  Biomark Med       Date:  2011-06       Impact factor: 2.851

5.  Personalized medicine and inhibition of EGFR signaling in lung cancer.

Authors:  Adi F Gazdar
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

6.  Screening for epidermal growth factor receptor mutations in lung cancer.

Authors:  Rafael Rosell; Teresa Moran; Cristina Queralt; Rut Porta; Felipe Cardenal; Carlos Camps; Margarita Majem; Guillermo Lopez-Vivanco; Dolores Isla; Mariano Provencio; Amelia Insa; Bartomeu Massuti; Jose Luis Gonzalez-Larriba; Luis Paz-Ares; Isabel Bover; Rosario Garcia-Campelo; Miguel Angel Moreno; Silvia Catot; Christian Rolfo; Noemi Reguart; Ramon Palmero; José Miguel Sánchez; Roman Bastus; Clara Mayo; Jordi Bertran-Alamillo; Miguel Angel Molina; Jose Javier Sanchez; Miquel Taron
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

Review 7.  The biology of epidermal growth factor receptor in lung cancer.

Authors:  Giorgio V Scagliotti; Giovanni Selvaggi; Silvia Novello; Fred R Hirsch
Journal:  Clin Cancer Res       Date:  2004-06-15       Impact factor: 12.531

8.  Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing.

Authors:  Azeet Narayan; Nicholas J Carriero; Scott N Gettinger; Jeannie Kluytenaar; Kevin R Kozak; Torunn I Yock; Nicole E Muscato; Pedro Ugarelli; Roy H Decker; Abhijit A Patel
Journal:  Cancer Res       Date:  2012-05-10       Impact factor: 12.701

9.  A tale of three next generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers.

Authors:  Michael A Quail; Miriam Smith; Paul Coupland; Thomas D Otto; Simon R Harris; Thomas R Connor; Anna Bertoni; Harold P Swerdlow; Yong Gu
Journal:  BMC Genomics       Date:  2012-07-24       Impact factor: 3.969

10.  Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells.

Authors:  Christopher R Zito; Lucia B Jilaveanu; Valsamo Anagnostou; David Rimm; Gerold Bepler; Sauveur-Michel Maira; Wolfgang Hackl; Robert Camp; Harriet M Kluger; Herta H Chao
Journal:  PLoS One       Date:  2012-02-15       Impact factor: 3.240

View more
  3 in total

Review 1.  [New development lines in immunology. Perspective of pathology].

Authors:  J Rüschoff; D Zielinski; E Heinmöller
Journal:  Pathologe       Date:  2013-11       Impact factor: 1.011

2.  Preferable background filtering for next-generation sequencing analysis in non-small cell lung cancer: pericarcinomatous tissues or peripheral blood lymphocytes?

Authors:  Yaxiong Zhang; Lianpeng Chang; Wenfeng Fang; Yunpeng Yang; Lanjun Zhang; Shaodong Hong; Huaqiang Zhou; Yanfang Guan; Xin Yi; Li Zhang
Journal:  Cancer Commun (Lond)       Date:  2019-06-13

3.  Risk prediction model for epithelial ovarian cancer using molecular markers and clinical characteristics.

Authors:  Meiying Zhang; Guanglei Zhuang; Xiangjun Sun; Yanying Shen; Aimin Zhao; Wen Di
Journal:  J Ovarian Res       Date:  2015-10-21       Impact factor: 4.234

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.